Temple City: COVID-19 Emergency Use Authorization for Fulgent Genetics
Fulgent Genetics, a provider of comprehensive genetic testing solutions, today said that its subsidiary, Fulgent Therapeutics, LLC, received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its RT-PCR test for the detection of SARS-CoV-2, the virus that causes COVID-19, by using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs). The company is offering end-to-end processing, analysis and reporting for its COVID-1
